These findings not only identify the mechanism of that liraglutide ameliorates T2DM-induced NAFLD by inhibiting ferroptosis via activation AMPK/ACC signaling, but also provide a new avenue for the treatment of T2DM-associated NAFLD. Here, ACACA is linked to metabolic dysfunction-associated steatotic liver disease.